Establishment of a Cell Model Based on FKBP12 Dimerization for Screening of FK506-like Neurotrophic Small Molecular Compounds

Abstract

FK506 is an efficient immunosuppressive agent with an increasing number of clinical applications. It has been approved to prevent rejection in transplant patients and be efficacious in several autoimmune diseases. Its immunosuppressive activity results from binding to receptor proteins designated as immunophilins (i.e., FKBP12, FK506 binding protein). Recent studies have suggested that FK506 can promote neurite outgrowth as a 2nd activity. Furthermore, it has been shown that the neurotrophic property of FK506 is independent of its immunosuppressive action. Although the mechanism of its neurotrophic activity has not yet been well elucidated, FKBP12 is identified as a drug target, and much effort has been directed toward the design of FKBP12-binding molecules, which are neurotrophic but nonimmunosuppressive, for clinical use. In this present study, the authors constructed a stable cell line, which underwent apoptosis upon treatment by AP20187, a wholly synthesized, cell-permeable dimeric FK506 derivative, based on FKBP12-mBax dimerization. This AP20187-mediated apoptosiswas rapidly reversed by the addition of an FKBP12-binding competitormolecule (FK506 or rapamycin), indicating that this cell line might be used to screen FK506 derivatives. Using the screening model, hundreds of synthetic FK506 analogs were analyzed. A promising compound, named N308, was obtained. The results showed that N308 could inhibit AP20187-induced gene-modified target cell apoptosis and elicit augmentation of neurite extension from both cultured PC-12 cells and chicken dorsal root ganglia cultures.

Keywords

FK506 neurotrophic FKBP12 dimerization Bax-mediated apoptosis competitive inhibition FKBP12 targeted compounds preliminary screening neurite extension

References

Starzl TE , Mkowka L , Todo S : FK506: a potential breakthrough in immunosuppression. Transplant Proc 1987;19:S3-S104.

Kino T , Goto T : Discovery of FK506 and update. Ann N Y Acad Sci 1993;685:13-21.

McDiarmid SV , Busuttil RW , Ascher NL , Burdick J , D'Alessandro AM , Esquivel C , et al: FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation: results from the U.S. Multicenter Trial. Transplantation 1995;59:530-536.

Schreiber SL : Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-287.

Fruman DA , Klee CB , Bierer BE , Burakoff SJ : Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992;89:3686-3690.

Bierer BE , Mattila PS , Standaert RF , Herzenberg LA , Burakoff SJ , Crabtree G , et al: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 1990;87:9231-9235.

Dumont FJ , Staruch MJ , Koprak SL , Siekierka JJ , Lin CS , Harrison R , et al: The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992;176:751-760.

Hamilton GS , Steiner JP : Immunophilins: beyond immunosuppression. J Med Chem 1998;41:5119-5143.

Sharkey J , Butcher SP : Immunophilinsmediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994;371:336-339.

10.

Lyons WE , George EB , Dawson TM , Steiner JP , Snyder SH : Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A 1994;91:3191-3195.

11.

Gold BG , Katoh K , Storm-Dickerson T : The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci 1995;15:7509-7516.

12.

Gold BG : FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol 1997;15:285-306.

13.

Gold BG , Zeleny-Pooley M , Wang MS , Chaturvedi P , Armistead DM : A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol 1997;147:269-278.

14.

Hamilton GS , Huang W , Connolly MA : FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease. Bioorg Med Chem Lett 1997;7:1785-1790.

15.

Steiner JP , Hamilton GS , Ross DT , Valentine HL , Guo H , Connolly MA , et al: Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci U S A 1997;94:2019-2024.

16.

Armistead DM : Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr D 1995;51:522-528.

17.

Becker DB , Jensen JN , Myckatyn TM , Doolabh VB , Hunter DA , Mackinnon SE : Effects of FKBP-12 ligands following tibial nerve injury in rats. J Reconstr Microsurg 2000;16:613-620.

18.

Gold BG : Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Invest Drug 2000;9:2331-2342.

19.

Guo X , Dawson VL , Dawson TM : Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 2001;13:1683-1693.

20.

Sich C , Improta S , Cowley DJ , Guenet C , Merly JP , Teufel M , et al: Solution structure of a neurotrophic ligand bound to FKBP12 and its effects on protein dynamics. Eur J Biochem 2000;267:5342-5355.

21.

Guo X , Dillman JF III , Dawson VL , Dawon TM : Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol 2001;50:6-16.

22.

Kupina NC , Detloff MR , Dutta S , Hall ED : Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury. J Cereb Blood Flow Metab 2002;22:1212-1221.

23.

Birge RB , Wadsworth S , Akakura R , Abeysinghe H , Kanojia R , Macielag M , et al: A role for Schwann cells in the neuroregenerative effects of a nonimmunosuppressive FK506 derivative, JNJ460. Neuroscience 2004;124:351-366.

24.

Yang W , Rozamus LW , Narula S , Rollins CT , Yuan R , Andrade LJ , et al: Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket. J Med Chem 2000;43:1135-1142.

25.

Amara JF , Clackson T , Rivera VM , Guo T , Keenan T , Natesan S , et al: A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci U S A 1997;94:10618-10623.

26.

Antonsson B , Montessuit S , Lauper S , Eskes R , Martinou JC : Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 2000;345:271-278.

27.

Antonsson B , Montessuit S , Sanchez B , Martina JC : Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001;276:11615-11623.

28.

Suzuki M , Youle RJ , Tjandra N : Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000;103:645-654.

29.

Gross A , Jochel J , Wei MC , Korsmeyer SJ : Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3878-3885.

30.

Spencer DM , Wandless TJ , Schreiber SL , Crabtree GR : Controlling signal transduction with synthetic ligands. Science 1993;262:1019-1024.

31.

Sun F , Li PY , Wang LW , Bartlam M , Shu CL , Shen BF , et al: Design and structure-based study of new potential FKBP12 inhibitors. Biophys J 2003;85:3194-3201.

32.

Greene LA , Tischler AS : Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 1976;73:2424-2428.

33.

Yanker BA , Benowitz LI , Villa-Komaroff L , Neve RL : Transfection of PC12 cells with the human GAP-43 gene: effects on neurite outgrowth and regeneration. Brain Res Mol Brain Res 1990;7:39-44.